Back
Incyte Corp. 10K Form
Buy
69
INCY
Incyte Corp.
Last Price:
$100.50
Seasonality Move:
26.29%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | INCY/Incyte Corp. Quarterly |
| 2023-10-31 | 10Q | INCY/Incyte Corp. Quarterly |
| 2023-08-01 | 10Q | INCY/Incyte Corp. Quarterly |
| 2023-05-02 | 10Q | INCY/Incyte Corp. Quarterly |
| 2022-11-01 | 10Q | INCY/Incyte Corp. Quarterly |
| 2022-08-02 | 10Q | INCY/Incyte Corp. Quarterly |
Receive INCY News And Ratings
See the #1 stock for the next 7 days that we like better than INCY
INCY Financial Statistics
Sales & Book Value
| Annual Sales: | $4.2B |
|---|---|
| Cash Flow: | $519.6M |
| Price / Cash Flow: | 17.23 |
| Annual Sales: | $23.71 |
| Price / Book: | 4.28 |
Profitability
| EPS (TTM): | 5.96100 |
|---|---|
| Net Income (TTM): | $1.2B |
| Gross Margin: | $3.9B |
| Return on Equity: | 31.1% |
| Return on Assets: | 20.93% |
Incyte Corp. Earnings Forecast
Key Incyte Corp. Financial Ratios
-
The Gross Profit Margin over the past 32 years for INCY is 91.09%.
-
The Selling, General & Administrative Expenses for INCY have been equal to 29.29% of Gross Profit Margin.
-
The Research & Development expenses have been 61.46% of Revenue.
-
The Interest Expense is 6.99% of Operating Income.
-
The Net Earning history of INCY is 0.77% of Total Revenues.
-
Per Share Earnings over the last 32 years have been positive in 17 years.
Incyte Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | INCY |
| CUSIP: | 45337C |
| Website: | incyte.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 3.2 |
| Quick Ratio: | 2.86 |
Price-to-Earnings
| Trailing P/E Ratio: | 655.26 |
|---|---|
| Forward P/E Ratio: | 13.11 |
INCY Technical Analysis vs Fundamental Analysis
Buy
69
Incyte Corp. (INCY)
is a Buy
Is Incyte Corp. a Buy or a Sell?
-
Incyte Corp. stock is rated a BuyThe current Incyte Corp. [INCY] share price is $101.50. The Score for INCY is 69, which is 38% above its historic median score of 50, and infers lower risk than normal.